Katerina Tatarinova

Ms. Katerina Tatarinova

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 December 2025 in ChemRxiv
Verified
Preprint
Open access
PDF file
DZDaniil Zhuravlev
Daniil Zhuravlev
KTKaterina Tatarinova
Katerina Tatarinova
DCDmitry Cheshev
Dmitry Cheshev
AMAlexander Maksimov
Alexander Maksimov
Veronica SulyaevaVeronica Sulyaeva
Veronica Sulyaeva
Pavel A. AbramovPavel A. Abramov
Pavel A. Abramov
The recent advancements in 11 group metal-organic chalcogenolates (MOCs) based materials raise questions about the preparation of MOC films. In this research, we demonstrate that polymeric [Ag(S-Arf)]n (Arf = perfluorinated aryl group) can be dissolved in pyridine and its homologues (py-R). These solutions can be used to process [Ag(S-Arf)]n using different methods. Crystallization from these solutions produces a new type of MOCs, [(py-R)Ag(S-Arf)]n, that are here systematically characterized by structural, spectroscopic, and computational techniques.

Verified
Journal Article
Open access
PDF file
DKDanil Kotelnikov
Danil Kotelnikov
KTKaterina Tatarinova
Katerina Tatarinova
DZDmitry D. Zhdanov
Dmitry D. Zhdanov
Despite global vaccination efforts, poliomyelitis continues to cause paralytic cases, highlighting the need for alternative therapeutic approaches. Nanobodies offer significant advantages over conventional antibodies due to their small size, stability, and low immunogenicity, yet few have been developed specifically against poliovirus. This study presents a fully computational pipeline for de novo design of nanobodies targeting Virus Protein 3 (VP3) of the Poliovirus I Sabin strain. Our integrated approach employed Ig-VAE for scaffold generation, ProteinMPNN and RFantibody for sequence design, tFold-Ab/Ag for structure prediction, multi-platform molecular docking (Rfantibody, Rosetta3, ClusPro2, ReplicaDock 2.0), molecular dynamics simulations, and humanization tools. The pipeline identified three humanized nanobodies (scFv-0389-304-6H, scFv-0389-459-5H, and scFv-0743-166-7/H) that demonstrated strong binding to VP3 with binding free energies of −37.66 ± 10.35, −40.11 ± 20.01, and −48.62 ± 11.21 kcal/mol, respectively. All designs exhibited favorable physicochemical properties and high solubility. Notably, nanobodies humanized prior to CDR-loop design (scFv-0743-166-7/H) showed superior stability, binding affinity, and structural similarity to experimentally validated nanobodies. This work demonstrates the feasibility of a fully computational approach for designing promising nanobodies against viral targets, providing an alternative to traditional methods with potential applications in drug design.